Comorbidity of depressive and dermatologic disorders - Therapeutic aspects

Psychiatria Danubina

Volumn 21, Issue 3, 2009, Pages 401-410

  Filaković, Pavo ^a   Petek, Anamarija ^b   Koić, Oliver ^a   Radanović Grgurić, Ljiljana ^b   Degmečić, Dunja ^a  

^a JOSIP JURAJ STROSSMAYER UNIVERSITY OF OSIJEK   (Croatia)

^b UNIVERSITY HOSPITAL OSIJEK   (Croatia)

Author keywords

Comorbidity; Depressive disorders; Dermatologic disorders; Therapeutic aspects

Indexed keywords

ACETYLSALICYLIC ACID; ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIHISTAMINIC AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBAMAZEPINE; CIMETIDINE; CORTICOSTEROID DERIVATIVE; DACARBAZINE; DOXEPIN; FAMOTIDINE; FLUOXETINE; HISTAMINE H2 RECEPTOR ANTAGONIST; METHOTREXATE; METHYLDOPA; NEUROLEPTIC AGENT; ORAL CONTRACEPTIVE AGENT; PAROXETINE; PHENYTOIN; PROCARBAZINE; RANITIDINE; RESERPINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TIANEPTINE; VINBLASTINE;

ANHEDONIA; ANOREXIA; ANXIETY; BLEEDING; COMORBIDITY; CONCENTRATION LOSS; CONFERENCE PAPER; DEPRESSION; DISEASE PREDISPOSITION; DRUG MECHANISM; EMOTIONAL STRESS; HUMAN; IATROGENIC DISEASE; IMMUNE RESPONSE; MENTAL STRESS; PSYCHOEDUCATION; PSYCHOPHYSIOLOGY; PSYCHOTHERAPY; SKIN DEFECT; SKIN DISEASE; SKIN PRURITUS; TREATMENT OUTCOME;

COMBINED MODALITY THERAPY; COMORBIDITY; COOPERATIVE BEHAVIOR; CYTOKINES; DEPRESSIVE DISORDER; HUMANS; INTERDISCIPLINARY COMMUNICATION; PATIENT CARE TEAM; PSYCHONEUROIMMUNOLOGY; REFERRAL AND CONSULTATION; RISK FACTORS; SKIN DISEASES;

EID: 70350309730     PISSN: 03535053     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (85)

1. Barnow S, Linden M, Lucht M & Freyberger H-J. The importance of psychosocial factors, gender, and severity of depression in distinguishing between adjustment and depressive disorders. Journal of Affective Disorders 2002; 72:71-78. (Pubitemid 35232165)
2. Boguniewicz M, Nicol N, Kelsay K & Leung DYM: A Multidisciplinary aproach to evaluation and treatment of atopic dermatitis. Semin Cutan med Surg 2008; 27:115-127. (Pubitemid 351953915)
3. Boranić M & Sabioncello Agabrilovac J: Psihoneuroimunologija - regulacija imunosti na razini organizma kao cjeline. Liječ Vjesn 2008; 130:62-67.
4. Braun-Falco O: Psoriasis vulgaris. In: Braun-Falco O, Plewig G, Burgdorf WHC, ur. Dermatology. Berlin/Heidelberg/New York: Springer Verlag; 2000.
5. Broadley AJ, Koerszun A, Jones CJ & Frenneaux MP: Arterial endotelial function is imparled in treated depression. Heart 2002; 88:521-523.
6. Buske-Kirschbaum A, Ebrecht M, Kern S, Gierens A & Hellhamer DH: Personality, characteristics in chronic and non-chronic allergic conditions. Brain Behaviour and Immunity 2008; 22:762-768.
7. Choi J & Koo YM: Quality of life issues in psoriasis. J Am Acad Dermatol 2003; 49:S57-S61.
8. Christophers E: Commorbidities in psoriasis. Clinics in Dermatology 2007; 25:529-534.
9. Cohen AD, Ofek-Shlomai A, Vardi DA, Weiner Z & Shvartzman P: Depression in dermatological patients identified by Mini International Neuropsychiatric Interview questionnaire. J Am Acad Dermatol 2006; 54(1):94-99. (Pubitemid 41832464)
10. Corcos M, Guilbaud O, Hjalmarsson L, Chambry J & Jeammet Ph: Cytokines and depression: an analogic approach. Biomed Pharmacother 2002; 56:105-110.
11. Costa de Silva JA: Overview of the field. Metabolism Clinical and Experimental 2005; (Suppl. 1):5-9.
12. Cristophers E & Sterry W: Psoriasis. In: Fitzpatrick TB, Eisen AZ, Wolff K, Freedberg IM & Austen KF, ur. Dermatology in general medicine. New York: Mc Graw-Hill, 1993; 489-511.
13. Dentino AN, Rao CF, Murali K, Currie MS, Harris T, Blazer DG & Cohen HJ: Association of interleukin-6 and other biologiv variables with depression in older people living in the community. J Am Geriatr Soc 1999;47:6-11. (Pubitemid 29044260)
14. Dhondt TD, Beekman AT, Deeg DJ & Van Tilburg W: Iatrogenic depression in the elderly. Results from a community-based study in the Netherlands. Soc Psychiatry Psychiatr Epidemiol 2002; 37(8):393-398
15. Dinarello CA. Therapeutic strategies to reduce IL-1 activity in treating local and systemic inflammation. Current Opinion in Pharmacology 2004; 4:378-385.
16. Dunn AJ, Swiergiel AH & de Beaurepaire R: Cytokines as mediators of depression : What can we learn from animal studies? Neuroscience and neurobehavioral Reviews 2005; 29:891-909.
17. Eastman CI, Young MA, Fogg LF, Liu L, Meaden PM. Bright light treatment of winter depression: a placebo-controlled trial. Arch Gen Psychiatry 1998; 55:883-889. (Pubitemid 28465777)
18. Elder JT, Nair JP, Sun-Wei G, Henseler T, Cristophers T & Voorhees JJ: The genetics of psoriasis. Arch Dermatol 1994; 130:216-224
19. Farber EM & Nell L: Psoriasis: a stress-related disease. Cutis 1993; 51(5):322-326
20. Fried RG, Gupta MA & Gupta AK: Depression and skin disease. Dermatologic Clinics 2005; 23(4):657-664.
21. Fried RG: Nonpharmacologic treatments in psychodermatology. Dermatologic Clinics 2002; 20(1):177-185.
22. Goodwin RD, Castro M & Kovacs M: Major depression and allergy: does neuroticism explain the relationship? Psychosomatic medicine 2006; 68:94-98.
23. Gregurek R. et al. Suradna i konzultativna psihijatrija. Psihijatrijski i psihološki problemi u somatskoj medicini. Školska knjiga, Zagreb, 2006.
24. Griffiths CEM & Barker JNW: Pathogenesis and clinical features of psoriasis. Lancet 2007; 370:263-71.
25. Gupta MA, Gupta AK, Ellis CN & Koblenzer CS: Psychiaric evaluation of the dermatology patients. Dermatologic Clinics 2005; 23(4):591-599.
26. Haack M, Hinze-Selch D, Fenzel T, Kraus T, Kühn M, Schuld A, et al. Plasma levels of cytokines and suluble cytokine receptors in psychiatric patients upon hospital admission: effects of confounding factors and diagnosis. J Psychiatr Res 1999; 33:407-418. (Pubitemid 29392689)
27. Himmerich H, Binder EB, Künzel HE, Schuld A, Lucae S Uhr M, et al. Succesful antidepressant therapy restores the disturbed interplay beetwen TNF-α system and HPA axis. Biol Psychiatry 2006; 60:882-888. (Pubitemid 44527894)
28. Himmerich H, Fulda S, Linseisen J, Seiler H, Wolfram G, Himmerich S, et al. Depression, comorbidities and the TNF-α system. European Psychiatry 2008;1-9 (in press) Available on line at www.science.direct.com
29. Himmerich H, Fulda S, Linseisen J, Seiler H, Wolfram G, Himmerich S, Gedrich K, Kloiber S, Lucae S, Ising M, Uhr M, Holsboer F & Pollmacher T: Depression, commorbidities and the TNF-alfa system. European Psychiatry 2008; 23:421-429.
30. Holland SM & Vizi ES: Immunomodulation. Current Opinion in Pharmacology 2002; 2:425-427.
31. Kaliterna D: Fototerapija. Pregled Zdravlje 2006; http://www.pregled.com/ zdravlje.php/
32. Kasper S & Oliè JP: A meta-analysis of randomized controlled trials of tianeptin versus SSRI in the short-term treatment of depression. Eur Psychiatry 2002; 17(Suppl 3):331-340. (Pubitemid 34839396)
33. Katsambas A & Papakonstantinou A: Acne: Systemic treatment. Clinics in Dermatology 2004; 22:412-418.
34. Katsambas AD & Stratigos AJ: Dermatologic therapy in the new millennium. Clinics in Dermatology 2001:19:65-67.
35. Kenreigh CA: Wagner LT. Viewpoint: Could psoriasis treatment have additional benefits? Lancet 2006; 367(9504):29-35.
36. Keshavan MS: Iatrogenic depression. In: Robertson MM, Katona CLE (eds). Depression and physical illness. Chichester. Wiley, 1997; 537-550.
37. Kiecolt-Glaser JK & Glaser R: Depression and immune function: central pathways to morbidity and mortality. J Psychosom Res 2002;53:873-876.
38. Kimball AB, Gladman D, Gelfand JM, Gordon K, Horn EJ, Korman NJ, et al. National psoriasis foundation clinical consensus on psoriasis comorbidities and recommendations for screening. J Am Acad Dermatol 2008; 58:1031-1042.
39. Koblentzer CS: Psychosomatic concept in dermatology. Arch Dermatol 1983; 119:501-512.
40. Konsman JP, Parnet P & Dantzer R: Cytokine-induced sickness behaviour: mechanisms and implications. Trends Neurosci 2002; 25:154-159.
41. Konuk N, Koca R, Atik L, Muhtar S, Atasoy N & Bostanci B: Psychopathology, depression and dissociative experiences in patients with lichen simplex chronicus. General Hospital Psychiatry 2007; 29:232-235. (Pubitemid 46678210)
42. Koo J & Lebwohl A: Psychodermatology: The mind and skin connection. Am Fam Physician 2001; 64(11):1873-1878.
43. Koo JY & Ng TC: Psychotropic and neurotropic agents in dermatology: unapproved uses, dosages, or indications. Clinics in Dermatology 2002; 20:582-594. (Pubitemid 35341691)
44. Kotrulja L & Šitum M: Psihodermatologija. Medix 2004; 54/55:143-145.
45. Kourosh AS, Miner A & Menter A: Psoriasis as the marker of underlying systemic disease. Skin Therapy Letter 2008; 13(1):1-5.
46. Krasowska D, Szymanek M, Schwartz RA & Myslinski W: Cutaneous effects of the most commonly used antidepressant medication, the selective serotonin reuptake inhibitors. J Am Acad Dermatol 2007; 56:848-853 (Pubitemid 46560997)
47. Kretzmer GE, Gelkopf M, Kretzmer G & Melamed Y: Idiopathic pruritus in psychiatric inpatients: an explorative study. General Hospital Psychiatry 2008; 30:344-348. (Pubitemid 351862317)
48. Lee CS & Koo J: Psychocutaneous drug therapy. Seminars in Cutaneous Medicine and Surgery 2003; 22(3):222-233.
49. Leonard BE: The immune system, depression and the action of antidepressants. Prog Neuropsychopharmacol and Biol Psychiatry 2001; 25:767-780. (Pubitemid 32374966)
50. Lett HS, Blumenthal JA, Babyak MA, Sherwood A, Strauman T, Robins C, et al. Depression as a risk factor for coronary artery disaesa: evidence, mechanims, and treatment. Psychosom Med 2004; 66:305-315. (Pubitemid 38668397)
51. Lipper G: Isotretinoin therapy and mood changes in adolescents with moderate to severe acne: a cohort study. Archives of Dermatology 2005; 114(5):557-560.
52. Livingston G, Watkin V, Milne B, Manela VM & Katona C: Who becomes depressed? The Islington community study of older people. J Affect Disord 2000; 58(2):125-133. (Pubitemid 30227308)
53. Maes M: Major depression and activation of the inflamantory response system. Adv Exp Med Biol 1999; 461:25-46. (Pubitemid 32192856)
54. Maubach KA, Rupniak NMJ, Kramer MS & Hill RG: Novel strategies for pharmacotherapy of depression. Current Opinion in Chemical Biology 1999; 3:481-488.
55. Miller AH, Maletić V & Raison CL: Inflammation and its discontents: the role of cytokines in the patophysiology of major depression. Biol Psychiatry 2009; 65:732-741.
56. Müller N & Schwarz MJ: Immunological aspects of depressive disorders. Nervenarzt 2007; 78:1261-1273.
57. Norton J, de Roquefeuil G, Benjamins A, Boulenger J-P & Mann A: Psychiatric morbiditi, disability and service use amongst primary care attenders in France. European Psychiatry 2004; 19:164-167. (Pubitemid 38670456)
58. O'Leary CJ, Creamer D, Higgins E & Weinman J: Perceived stress, attributions and psychological distress in psoriasis. Journal of Psychosomatic Research 2004; 57:465-471. (Pubitemid 39577639)
59. Picardi A, Mazzotti E & Pasquini P: Prevalence and correlates of suicidal ideation among patients with skin disease. J Am Acad Dermatol 2006; 54(3):420-426. (Pubitemid 43243444)
60. Pietrzak AT, Zalewska A, Chodorowska G, Krasowska D, Michalak-Stoma A, et al. Cytokines and anticytokines in psoriasis. Clinica Chimica Acta 2008; 394:7-21.
61. Pike JL & Irwin MR: Dissociation of inflamatory markers and natural killer cell activity in major depressive disorder. Brain Behav Immun 2006; 20:169-174.
62. Posternak M & Zimmerman M: Lack of association between seasonality and psychopathology in psychiatric outpatients. Psychiatry Research 2002; 112:187-194. (Pubitemid 35351720)
63. Raison CL, Capuron L & Miller AH: Cytokines, sing the blues: inflammation and the pathogenesis of depression. TRENDS in Immunology 2006; 27(1):24-31. (Pubitemid 43083561)
64. Runkewitz K, Kirchmann H & Strauss B: Anxiety and depression in primary care patients: Predictors of symptom severity and developmental correlates. Journal of Psychosomatic Research 2006; 60:445-453.
65. Schmid-Ott G, Jaeger B, Boehm T, Langer K, Stephan M, Raap U & Werfel T: Immunological effects of stress in psoriasis. Abstract. Br J Dermatology 2009; 160(4):782-785.
66. Schmitt J & Ford DE: Understanding the relationship between objective disease severity, psoriatic symptoms. Illness-related stress, health-related quality of life and depressive symptoms in patients with psoriasis - a structural equations modeling aproach. General Hospital Psychiatry 2007;29:134-140.
67. Soczynska JK, Kennedy SH, Goldstein BI, Lachowski A, Woldeyohannes HO & McInture RS: The effect of tumor necrosis factor antagonists on mood and mental health-associated quality of life: Novel hypothesis-driven treatments for bipolar depression? Neurotoxicology 2009; (in press) doi:10.1006/j.neuro.2009. 03.004.
68. Sokal S: Poboljšanje rada imunološkog sustava - psihološke intervencije. Hrvatski časopis za javno zdravstvo 2007; 3(10): http://www.hcjz.hr/clanak.php
69. Stewart JC, Rand KL, Muldoon MF & Kamarck TW: Brain, behaviour, and immunity. 2009; (in press, available at ScienceDirect: www.elsevier.com/locate/ ybrbi)
70. Stone SP: Comment and controversy. Clinics in Dermatology 2001; 19:360-363.
71. Szelènyi J & Selmeczy Z: Immunomodulatory effect of antidepressants. Current Opinion in Pharmacology 2002; 2:428-432.
72. Taylor E, Bewley A & Melidonis N: Psychodermatology. Psychiatry and medicine 2006; 5(3):81-84.
73. Urpe M, Pallanti S & Lotti T: Psychosomatic factors in dermatology. Dermatologic Clinics 2005; 23(4):601-608.
74. Van Moffaert M: Psychodermatology: an overview. Psychoter Psychosom 1992;58:125-136.
75. Vedhara K, Morris RM, Booth R, Horgan M, Lawrence M& Birchall N: Changes in mood predict disease activity and quality of life in patients with psoriasis following emotional disclosure. Journal of Psychosomatic Research 2007; 62:611-619. (Pubitemid 46823987)
76. Vitkovic L, Bockaert J & Jacque C: "Inflammatory" cytokines: neuromodulators in normal brain? J Neurochem 2000; 74(2):457-471.
77. Walker Z & Katona C: Depression in elderly people with physical illness. In: Robertson MM, Katona CLE (eds). Depression and physical illness. Chichester. Wiley, 1997; 169-181.
78. Wamboldt MZ, Hewitt FK, Schmitz S, Wamboldt FS, Rasanen M, Koskenvuo M, Romanov K, Varjonen J & Kaprio J: Familial association between alergic disorder and depression in adult Finnish twins. Am J Med Genet 2000;96:146-153. (Pubitemid 30180852)
79. Watson T & de Bruin D: Getting under the skin: The inscription of dermatological disease on the self-concept. Indo-Pacific Journal of Phenomenology /www.ipjp.org./ 2006; 6(1):1-12.
80. Wittkowski A, Richards HL, Griffiths CEM & Main CJ: The impact of psychological and clinical factors on quality of life in individuals with atopic dermatitis. Journal of Psychosomatic Research 2004; 57:195-200. (Pubitemid 39296815)
81. World Health Organization. The world health report 2001 - mental health: New understanding. Geneve. WHO; 2001.
82. Wright CE, Strike PC, Brydon L & Steptoe A: Acute inflammation and negative mood: Mediation by cytokine activation. Brain Behaviour and immunity 2005; 19:345-350. (Pubitemid 40797991)
83. Yamakawa K, Matsunaga M, Isowa T, Kimura K, Kasugai K, Yoneda M, Kaneko H & Ohira H: Transient responses of inflammatory cytokines in acute stress. Biological Psychology 2009; (in press, available at ScienceDirect: www.elsevier.com/locate/biopsycho)
84. Zhu CB, Blakely RD & Hewlett WA: The pronflamatory cytokines interleukin1-beta and tumor necrosis factor-alpha activate serotonin transporters. Neuropsychopharmacology 2006; 31:2121-2131.
85. Zorrila EP, Luborsky L, McKay JR, Rosenthal R, Houldin A, Tax A, et al. The relationship of depression and stressors to immunological assays: a meta-analytic review. Brain Behav Immun 2001; 15:199-226. (Pubitemid 33070955)